{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:36:15Z","timestamp":1761744975400,"version":"build-2065373602"},"reference-count":98,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.dsx.2019.03.031","type":"journal-article","created":{"date-parts":[[2019,3,17]],"date-time":"2019-03-17T17:32:30Z","timestamp":1552843950000},"page":"1679-1683","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes"],"prefix":"10.1016","volume":"13","author":[{"given":"Habib","family":"Yaribeygi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen L.","family":"Atkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dsx.2019.03.031_bib1","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa1610187","article-title":"Incidence trends of type 1 and type 2 diabetes among youths, 2002\u20132012","volume":"376","author":"Mayer-Davis","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dsx.2019.03.031_bib2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.metabol.2018.07.001","article-title":"MicroRNAs and type 2 diabetes mellitus: molecular mechanisms and the effect of antidiabetic drug treatment","volume":"87","author":"Yaribeygi","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.dsx.2019.03.031_bib3","doi-asserted-by":"crossref","first-page":"7458","DOI":"10.1002\/jcb.27055","article-title":"Fenofibrate improves renal function by amelioration of NOX-4, IL-18, and p53 expression in an experimental model of diabetic nephropathy","volume":"119","author":"Yaribeygi","year":"2018","journal-title":"J\u00a0Cell Biochem"},{"key":"10.1016\/j.dsx.2019.03.031_bib4","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1002\/jcp.27278","article-title":"Antioxidative potential of antidiabetic agents: a possible protective mechanism against vascular complications in diabetic patients","volume":"234","author":"Yaribeygi","year":"2019","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.dsx.2019.03.031_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/jcp.28066","article-title":"Molecular mechanisms by which aerobic exercise induces insulin sensitivity","author":"Yaribeygi","year":"2019","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.dsx.2019.03.031_bib6","doi-asserted-by":"crossref","first-page":"5786","DOI":"10.1002\/jcp.27503","article-title":"Narrative review of the effects of antidiabetic drugs on albuminuria","volume":"234","author":"Yaribeygi","year":"2019","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.dsx.2019.03.031_bib7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.drudis.2018.08.005","article-title":"Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys","volume":"24","author":"Yaribeygi","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.dsx.2019.03.031_bib8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jcp.26851","article-title":"Sodium\u2013glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: possible molecular pathways","volume":"234","author":"Yaribeygi","year":"2019","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.dsx.2019.03.031_bib9","doi-asserted-by":"crossref","first-page":"8286","DOI":"10.1002\/jcp.27699","article-title":"A\u00a0review of the anti-inflammatory properties of antidiabetic agents providing protective effects against vascular complications in diabetes","volume":"234","author":"Yaribeygi","year":"2018","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.dsx.2019.03.031_bib10","first-page":"3","volume":"vol 34","author":"Association","year":"2016"},{"key":"10.1016\/j.dsx.2019.03.031_bib11","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1002\/jcp.26760","article-title":"Sodium\u2013glucose cotransporter inhibitors and oxidative stress: an update","volume":"234","author":"Yaribeygi","year":"2019","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.dsx.2019.03.031_bib12","first-page":"33","article-title":"Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes","volume":"126","author":"Davidson","year":"2014","journal-title":"PGM (Postgrad Med)"},{"key":"10.1016\/j.dsx.2019.03.031_bib13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2337\/diaclin.32.1.4","article-title":"SGLT-2 inhibitors: a new mechanism for glycemic control","volume":"32","author":"Chao","year":"2014","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.dsx.2019.03.031_bib14","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/jsfa.6779","article-title":"Acute anti-hyperglycaemic effects of an unripe apple preparation containing phlorizin in healthy volunteers: a preliminary study","volume":"95","author":"Makarova","year":"2015","journal-title":"J\u00a0Sci Food Agric"},{"key":"10.1016\/j.dsx.2019.03.031_bib15","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","article-title":"SGLT2 inhibition\u2014a novel strategy for diabetes treatment","volume":"9","author":"Chao","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.dsx.2019.03.031_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001007","article-title":"Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes","volume":"2","author":"Clar","year":"2012","journal-title":"BMJ open"},{"key":"10.1016\/j.dsx.2019.03.031_bib17","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.metabol.2015.10.010","article-title":"The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db\/db mice both as monotherapy and in combination with linagliptin","volume":"65","author":"Kern","year":"2016","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.dsx.2019.03.031_bib18","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2337\/db07-1472","article-title":"Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats","volume":"57","author":"Han","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.dsx.2019.03.031_bib19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/dom.12187","article-title":"Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years","volume":"16","author":"Wilding","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.dsx.2019.03.031_bib20","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J\u00a0Clin Investig"},{"key":"10.1016\/j.dsx.2019.03.031_bib21","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.2337\/dc14-S081","article-title":"Diagnosis and classification of diabetes mellitus","volume":"37","author":"Association","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2019.03.031_bib22","series-title":"Classification of diabetes. Diabetes","first-page":"12","author":"de Faria Maraschin","year":"2013"},{"key":"10.1016\/j.dsx.2019.03.031_bib23","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2337\/ds15-0047","article-title":"Recognizing and appropriately treating latent autoimmune diabetes in adults","volume":"29","author":"O'Neal","year":"2016","journal-title":"Diabetes Spectr"},{"key":"10.1016\/j.dsx.2019.03.031_bib24","first-page":"1","article-title":"Hypertension with diabetes mellitus complications","author":"Yamazaki","year":"2018","journal-title":"Hypertens Res"},{"key":"10.1016\/j.dsx.2019.03.031_bib25","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1751-7176.2011.00434.x","article-title":"Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection","volume":"13","author":"Long","year":"2011","journal-title":"J\u00a0Clin Hypertens"},{"key":"10.1016\/j.dsx.2019.03.031_bib26","first-page":"216","article-title":"The role of haemodynamic and metabolic factors in the development of diabetic nephropathy","volume":"26","author":"Grzeszczak","year":"2013","journal-title":"Post\u0119py Nauk Medycznych."},{"key":"10.1016\/j.dsx.2019.03.031_bib27","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1681\/ASN.2016060666","article-title":"Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment","volume":"28","author":"Tonneijck","year":"2017","journal-title":"J\u00a0Am Soc Nephrol: JASN (J Am Soc Nephrol)"},{"key":"10.1016\/j.dsx.2019.03.031_bib28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/dbi16-0056","article-title":"Back to the future: glomerular hyperfiltration and the diabetic kidney","volume":"66","author":"Tuttle","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.dsx.2019.03.031_bib29","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1001\/jama.299.14.1678","article-title":"Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial","volume":"299","author":"Howard","year":"2008","journal-title":"Jama"},{"key":"10.1016\/j.dsx.2019.03.031_bib30","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/archinte.165.12.1410","article-title":"Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials","volume":"165","author":"Trialists'Collaboration","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.dsx.2019.03.031_bib31","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.atherosclerosis.2014.12.023","article-title":"Arterial stiffness in diabetes mellitus","volume":"238","author":"Prenner","year":"2015","journal-title":"Atherosclerosis"},{"year":"2018","series-title":"Hemodynamic considerations in the pathophysiology of peripheral neuropathy. Blood pressure-from bench to bed","author":"Smith","key":"10.1016\/j.dsx.2019.03.031_bib32"},{"key":"10.1016\/j.dsx.2019.03.031_bib33","series-title":"Engineering in medicine and biology society (EMBC), 2015 37th annual international conference of the IEEE","first-page":"8070","article-title":"Characterization of parafoveal hemodynamics associated with diabetic retinopathy with adaptive optics scanning laser ophthalmoscopy and computational fluid dynamics","author":"Bernabeu","year":"2015"},{"key":"10.1016\/j.dsx.2019.03.031_bib34","first-page":"457","article-title":"Hemodynamic effects of sodium-glucose cotransporter 2 inhibitors","volume":"9","author":"Sano","year":"2017","journal-title":"J\u00a0Clin Med Res"},{"key":"10.1016\/j.dsx.2019.03.031_bib35","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/jdi.12644","article-title":"Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus","volume":"8","author":"Kashiwagi","year":"2017","journal-title":"J\u00a0diabetes investig"},{"key":"10.1016\/j.dsx.2019.03.031_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11886-018-0943-5","article-title":"SGLT2 inhibitors and mechanisms of hypertension","volume":"20","author":"Briasoulis","year":"2018","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.dsx.2019.03.031_bib37","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2337\/dc14-1596","article-title":"Blood pressure reduction: an added benefit of sodium\u2013glucose cotransporter 2 inhibitors in patients with type 2 diabetes","volume":"38","author":"Majewski","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2019.03.031_bib38","article-title":"Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients","volume":"6","author":"Mazidi","year":"2017","journal-title":"J\u00a0Am Heart Assoc."},{"key":"10.1016\/j.dsx.2019.03.031_bib39","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.2337\/dc11-1926","article-title":"Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2019.03.031_bib40","first-page":"346","article-title":"Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials","volume":"128","author":"Johnsson","year":"2016","journal-title":"PGM (Postgrad Med)"},{"key":"10.1016\/j.dsx.2019.03.031_bib41","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12933-018-0695-y","article-title":"Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy","volume":"17","author":"Irace","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.dsx.2019.03.031_bib42","doi-asserted-by":"crossref","first-page":"700","DOI":"10.2215\/CJN.06080616","article-title":"SGLT2 inhibition in the diabetic kidney\u2014from mechanisms to clinical outcome","volume":"12","author":"van Bommel","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.dsx.2019.03.031_bib43","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1161\/CIRCRESAHA.114.302524","article-title":"The autonomic nervous system and hypertension","volume":"114","author":"Mancia","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.dsx.2019.03.031_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2018.00421","article-title":"The effects of sodium-glucose cotransporter 2 inhibitors on sympathetic nervous activity","volume":"9","author":"Wan","year":"2018","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.dsx.2019.03.031_bib45","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1080\/03007995.2016.1201465","article-title":"Cardiovascular effects of sodium\u2013glucose cotransporter 2 inhibitors: multiple actions","volume":"32","author":"Katsiki","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.dsx.2019.03.031_bib46","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.dsx.2019.03.031_bib47","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME\u00ae trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.dsx.2019.03.031_bib48","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2337\/dc16-0041","article-title":"SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study","volume":"39","author":"Abdul-Ghani","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2019.03.031_bib49","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dsx.2019.03.031_bib50","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1097\/HJH.0000000000001434","article-title":"Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2","volume":"35","author":"Matthews","year":"2017","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.dsx.2019.03.031_bib51","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/dc11-1693","article-title":"Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2019.03.031_bib52","first-page":"DC_133055","article-title":"Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes","author":"Rosenstock","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2019.03.031_bib53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1161\/01.HYP.0000151325.83008.b4","article-title":"Obesity-associated hypertension: new insights into mechanisms","volume":"45","author":"Rahmouni","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.dsx.2019.03.031_bib54","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/obr.12391","article-title":"The effect of dietary approaches to stop hypertension (DASH) diet on weight and body composition in adults: a systematic review and meta-analysis of randomized controlled clinical trials","volume":"17","author":"Soltani","year":"2016","journal-title":"Obes Rev"},{"key":"10.1016\/j.dsx.2019.03.031_bib55","first-page":"557","article-title":"Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults","volume":"33","author":"Leung","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.dsx.2019.03.031_bib56","series-title":"Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis. Diabetology & metabolic syndrome","first-page":"A58","author":"Pinto","year":"2015"},{"key":"10.1016\/j.dsx.2019.03.031_bib57","first-page":"199","article-title":"Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus","volume":"21","author":"Ribola","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.dsx.2019.03.031_bib58","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00467-017-3848-4","article-title":"Changes in arterial pressure and markers of nitric oxide homeostasis and oxidative stress following surgical correction of hydronephrosis in children","volume":"33","author":"Al-Mashhadi","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.dsx.2019.03.031_bib59","first-page":"83","article-title":"Nitric oxide and homeostasis of the smooth vascular muscle","volume":"86","author":"Schini","year":"1993","journal-title":"Arch Mal Coeur Vaiss"},{"key":"10.1016\/j.dsx.2019.03.031_bib60","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/clinchem\/44.8.1809","article-title":"Role of nitric oxide in cardiovascular disease: focus on the endothelium","volume":"44","author":"Cannon","year":"1998","journal-title":"Clin Chem"},{"key":"10.1016\/j.dsx.2019.03.031_bib61","doi-asserted-by":"crossref","first-page":"L1027","DOI":"10.1152\/ajplung.00167.2015","article-title":"SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery","volume":"309","author":"Han","year":"2015","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.dsx.2019.03.031_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112394","article-title":"The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity","volume":"9","author":"Oelze","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.dsx.2019.03.031_bib63","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1475-2840-12-70","article-title":"The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study","volume":"12","author":"Ring","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.dsx.2019.03.031_bib64","doi-asserted-by":"crossref","DOI":"10.1161\/hyp.72.suppl_1.P119","article-title":"Abstract P119: hypertension and renal dysfunction are mitigated by surgical renal denervation in an adult rat model of polycystic kidney disease","volume":"72","author":"Banek","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.dsx.2019.03.031_bib65","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/MJT.0000000000000202","article-title":"A\u00a0systematic review on the efficacy of amlodipine in the treatment of patients with hypertension with concomitant diabetes mellitus and\/or renal dysfunction, when compared with other classes of antihypertensive medication","volume":"22","author":"Jeffers","year":"2015","journal-title":"Am J Therapeut"},{"key":"10.1016\/j.dsx.2019.03.031_bib66","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11010-015-2439-6","article-title":"Contribution of mitochondrial function to exercise-induced attenuation of renal dysfunction in spontaneously hypertensive rats","volume":"406","author":"Gu","year":"2015","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.dsx.2019.03.031_bib67","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.2337\/dcS15-3006","article-title":"SGLT2 inhibitors and the diabetic kidney","volume":"39","author":"Fioretto","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2019.03.031_bib68","first-page":"1","article-title":"Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease","author":"Kelly","year":"2018","journal-title":"PGM (Postgrad Med)"},{"key":"10.1016\/j.dsx.2019.03.031_bib69","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/1871527317666180425122557","article-title":"The underlying role of oxidative stress in neurodegeneration: a mechanistic review","volume":"17","author":"Yaribeygi","year":"2018","journal-title":"CNS Neurol Disord - Drug Targets"},{"key":"10.1016\/j.dsx.2019.03.031_bib70","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1440-1797.2012.01572.x","article-title":"Oxidative stress, anti-oxidant therapies and chronic kidney disease","volume":"17","author":"Small","year":"2012","journal-title":"Nephrology"},{"key":"10.1016\/j.dsx.2019.03.031_bib71","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1474-9726.2006.00224.x","article-title":"Insulin resistance, oxidative stress, hypertension, and leukocyte telomere length in men from the Framingham Heart Study","volume":"5","author":"Demissie","year":"2006","journal-title":"Aging Cell"},{"key":"10.1016\/j.dsx.2019.03.031_bib72","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11906-010-0100-z","article-title":"Oxidative stress and hypertension: current concepts","volume":"12","author":"Briones","year":"2010","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.dsx.2019.03.031_bib73","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1161\/01.HYP.0000138070.47616.9d","article-title":"Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance?","volume":"44","author":"Touyz","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.dsx.2019.03.031_bib74","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/01.ATV.0000150649.39934.13","article-title":"Oxidative stress and vascular disease","volume":"25","author":"Madamanchi","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.dsx.2019.03.031_bib75","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/542042","article-title":"Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats","volume":"2012","author":"Osorio","year":"2012","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.dsx.2019.03.031_bib76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165703","article-title":"Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes","volume":"11","author":"Shin","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.dsx.2019.03.031_bib77","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13098-017-0258-5","article-title":"Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring","volume":"9","author":"Torimoto","year":"2017","journal-title":"Diabetol Metab Syndrome"},{"key":"10.1016\/j.dsx.2019.03.031_bib78","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1007\/s12325-016-0379-5","article-title":"Sodium-glucose cotransporter-2 inhibition and the glomerulus: a review","volume":"33","author":"Kalra","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.dsx.2019.03.031_bib79","first-page":"471","article-title":"A\u00a0new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity","volume":"71","author":"Sano","year":"2018","journal-title":"J\u00a0Cardiol"},{"key":"10.1016\/j.dsx.2019.03.031_bib80","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.dsx.2019.03.031_bib81","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2017.06.017","article-title":"Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin","volume":"93","author":"Cherney","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.dsx.2019.03.031_bib82","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc14-2364","article-title":"Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin","volume":"38","author":"DeFronzo","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2019.03.031_bib83","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S2213-8587(17)30308-X","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial","volume":"5","author":"Dandona","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.dsx.2019.03.031_bib84","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"Fr\u00edas","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.dsx.2019.03.031_bib85","doi-asserted-by":"crossref","first-page":"286","DOI":"10.4103\/ijem.IJEM_517_16","article-title":"Long-term efficacy and safety of empagliflozin monotherapy in drug-na\u00efve patients with type 2 diabetes in Indian subgroup: results from a 76-week extension trial of phase iii, double-blind, randomized study","volume":"21","author":"Gupta","year":"2017","journal-title":"Indian J Endocrinol Metabol"},{"key":"10.1016\/j.dsx.2019.03.031_bib86","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/dom.13124","article-title":"Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb\/III clinical trials","volume":"20","author":"Jabbour","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.dsx.2019.03.031_bib87","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/jdi.12422","article-title":"Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial","volume":"7","author":"Lu","year":"2016","journal-title":"J\u00a0diabetes investig"},{"key":"10.1016\/j.dsx.2019.03.031_bib88","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4093\/dmj.2017.41.2.135","article-title":"Addition of ipragliflozin to metformin treatment in Korean patients with type 2 diabetes mellitus: subgroup analysis of a phase 3 trial","volume":"41","author":"Min","year":"2017","journal-title":"Diabetes Metabol J"},{"key":"10.1016\/j.dsx.2019.03.031_bib89","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","article-title":"Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial","volume":"2","author":"Ridderstr\u00e5le","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.dsx.2019.03.031_bib90","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12933-015-0314-0","article-title":"Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-na\u00efve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial","volume":"14","author":"Roden","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.dsx.2019.03.031_bib91","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/dc11-0606","article-title":"Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial","volume":"34","author":"Nauck","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2019.03.031_bib92","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","article-title":"Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"1","author":"Roden","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.dsx.2019.03.031_bib93","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.diabres.2018.10.018","article-title":"A\u00a0phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus","volume":"146","author":"Shestakova","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.dsx.2019.03.031_bib94","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.dsx.2019.03.031_bib95","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1111\/dom.13351","article-title":"Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial","volume":"20","author":"Shimada","year":"2018","journal-title":"Diabetes Obes Metab"},{"year":"2018","series-title":"Safety and tolerability of empagliflozin in east asian patients with type 2 diabetes\u2014pooled analysis of phase I-iii clinical trials","author":"YASUI","key":"10.1016\/j.dsx.2019.03.031_bib96"},{"key":"10.1016\/j.dsx.2019.03.031_bib97","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2019.03.031_bib98","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015766","volume":"7","author":"Koshizaka","year":"2017","journal-title":"BMJ open"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402119301389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402119301389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:05:45Z","timestamp":1761728745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402119301389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":98,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1871402119301389"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2019.03.031","relation":{},"ISSN":["1871-4021"],"issn-type":[{"type":"print","value":"1871-4021"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2019.03.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Diabetes India. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}